Start here if you're new
what it is
Pediatrix runs newborn, maternal-fetal, and pediatric care through 2,335 affiliated physicians in 36 states.
how it gets paid
Last year Pediatrix Medical made $1.9B in revenue. Neonatal clinical care was the main engine at $1.1B, or 57% of sales.
why growth slowed
Revenue fell 4.9% last year. The key number was $0.84 EPS, which beat $0.50 by 68.0% and kept the print ahead of expectations.
what just happened
Pediatrix beat estimates with $0.84 EPS versus $0.50 expected.
At a glance
B balance sheet — gets the job done, barely
40/100 earnings predictability — expect surprises
9.1x trailing p/e — the market's not buying it — or you found a deal
3.3% return on capital — nothing to write home about
$0.28 fy2024 eps est
xvary composite: 53/100 — below average
What they do
Pediatrix runs newborn, maternal-fetal, and pediatric care through 2,335 affiliated physicians in 36 states.
Your local NICU does not swap doctor teams like office supplies. Pediatrix has 2,335 affiliated physicians, including 1,335 neonatal doctors, across 36 states. That scale matters because hospitals need the people on site, not a box on a shelf.
How they make money
$1.9B
annual revenue · their business grew -4.9% last year
Neonatal clinical care
$1.1B
Maternal-fetal and obstetric care
$0.4B
Pediatric subspecialty care
$0.4B
The products that matter
newborn intensive care
Neonatology & Newborn Care
$1.3B · 68% of revenue
this is the center of gravity at $1.3B, but it declined 2.7%. if the biggest segment is shrinking, the rest of the portfolio needs to work harder just to keep company revenue flat.
core
high-risk pregnancy care
Maternal-Fetal & Women's Health
$380M · 20% of revenue
it contributes $380M and was flat in the latest full-year view. that makes it meaningful to the story, but not yet the segment pulling the whole company forward.
second line
specialty pediatric care
Pediatric Subspecialties
$220M · 12% of revenue
at $220M, it is the smallest of the three major segments and was also flat. it helps diversify the revenue base, but today it is not large enough to offset weakness in neonatology on its own.
supporting piece
Key numbers
9.1x
trailing p/e
P/E → price for earnings → you pay $9.10 for $1 of annual profit.
7.6%
operating margin
Operating margin → profit after running costs → you keep $7.60 from every $100 of sales.
3.3%
return on capital
Return on capital → profit from money tied up in the business → $100 invested earns $3.30.
$605M
long-term debt
Debt → borrowed money due later → $605M sits ahead of shareholders, or 27% of capital.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 3 — safer than 50% of stocks
- price stability 30 / 100
- long-term debt $605M (27% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for MD right now.
source: institutional data · return history unavailable
What just happened
beat estimates
Pediatrix beat estimates with $0.84 EPS versus $0.50 expected.
EDGAR shows $1.4B revenue in the latest quarter. Yahoo shows a 68.0% EPS surprise, and gross margin was not provided.
$1.4B
revenue
$0.84
eps
n/a
n/a
the number that mattered
The key number was $0.84 EPS, which beat $0.50 by 68.0% and kept the print ahead of expectations.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk here is not abstract healthcare noise. it's clinical labor inflation hitting a business with a 7.6% operating margin and a core segment already moving backward.
med
clinical compensation inflation
Pediatrix sells physician labor. When doctor and nurse compensation rises faster than reimbursement, the spread gets squeezed. On a 7.6% operating margin, you do not need a catastrophe for profit to feel it.
Why it matters: this is a margin story before it becomes a revenue story.
med
neonatology volume pressure
Neonatology & Newborn Care is $1.3B and 68% of revenue. It declined 2.7%. If the biggest segment keeps shrinking, flat results elsewhere stop looking stable and start looking insufficient.
Why it matters: the company is more concentrated than the three-segment layout first suggests.
med
cheap-stock trap
The stock trades at 9.1x trailing earnings, which looks inexpensive. But low multiples are often a warning label when return on capital is only 3.3% and earnings predictability is 40/100.
Why it matters: if investors decide the earnings base is lower quality than it looks, the multiple does not have to expand just because it already seems low.
With $605M of long-term debt, a 7.6% operating margin, and 68% of revenue tied to one segment, this business does not have a giant cushion for labor inflation or core-volume slippage.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
neonatology revenue trend
The core segment is $1.3B and fell 2.7%. If that line keeps shrinking, the whole "cheap defensive healthcare" case gets harder to defend.
risk
clinical pay versus margin
A 7.6% operating margin is workable, not generous. Watch whether labor costs keep eating the spread.
calendar
next earnings update
Use the next report to see whether flat revenue stayed flat for the right reason, or whether management is still relying on stability language to cover softness underneath.
trend
whether the smaller segments start pulling weight
Maternal-Fetal at $380M and Pediatric Subspecialties at $220M were both flat. You want at least one of them doing more than standing still.
Analyst rankings
short-term outlook
mixed
target data is thin here. in human-speak, analysts do not have a strong shared view.
risk profile
elevated
30/100 price stability and 40/100 earnings predictability tell you this can swing more than the business description suggests.
chart momentum
range-bound
the stock has traded between $12 and $25 over the last 52 weeks. welcome to a name the market keeps re-underwriting.
earnings predictability
40/100
these earnings are not bond coupons. reimbursement, labor, and segment mix can move the result around.
source: institutional data
Institutional activity
institutional ownership data for MD is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$22
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive